# Artiva Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/artiva-biotherapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.artivabio.com
- Total disclosed funding: $201M
- Latest round: Series B (Feb 22, 2021)
- Investors on record: 16

## About

Artiva Biotherapeutics, Inc. is a biotechnology firm focused on developing innovative natural killer (NK) cell-based therapies to enhance treatments for autoimmune diseases and certain cancers.Founded in 2019 and headquartered in San Diego, US, Artiva Biotherapeutics, Inc. specializes in NK cell therapies. The company, led by CEO Fred Aslan and founded by Peter Flynn, has raised a total of USD 120.00 mn in funding through multiple rounds, with the latest being a Series B round led by Venrock Healthcare Capital Partners. The company has completed 3 deals, with the most recent deal dated July 18, 2024.Artiva Biotherapeutics develops NK cell-based therapies, with its lead candidate, AlloNK®, designed to improve the efficacy of monoclonal antibodies in treating autoimmune diseases and cancers. AlloNK® is undergoing clinical trials for systemic lupus erythematosus and non-Hodgkin lymphoma, and aims to enhance treatment options for patients in the US and Europe.In 2023, Artiva Biotherapeutics generated revenue of USD 33.49 mn, with an EBITDA of USD -28.41 mn, centered around the development and potential commercialization of its NK cell therapy products, especially AlloNK®. Revenue will be driven by partnerships with biotechnology firms and potential direct sales following successful product approvals.Following a successful IPO on July 18, 2024, where Artiva Biotherapeutics, Inc. raised USD 167.04 mn by selling shares on the Nasdaq Global Select Market under the ticker symbol 'ARTV', the company plans to enhance its clinical development and operational infrastructure. The recent funding will support the expansion of its NK cell therapy offerings and allow for potential entry into new markets. The company continues to prioritize its lead product candidate, AlloNK®, with goals set for broader market penetration in 2024 and beyond.

## Funding rounds

- Series B, Feb 22, 2021, $120M — 5AM Ventures, Green Cross Corporation, VenBio, RTW Investments, RA Capital Management, EcoR1 Capital, Cormorant Asset Management, Acuta Capital Partners, Franklin Templeton, Janus Henderson Investors, Wellington Management Company, Surveyor Capital, Green Cross LabCell Corporation, Venrock Healthcare Capital Partners, Logos Capital
- Series A, Jun 26, 2020, $81M — 5AM Ventures, Green Cross Corporation, VenBio, RA Capital Management, LINEA Investment, Green Cross LabCell Corporation

## Investors

- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A, Series B
- Green Cross Corporation — Series A, Series B
- VenBio (https://capitalatlas.ai/funds/venbio) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- LINEA Investment (https://capitalatlas.ai/funds/linea-investment) — Series A
- Green Cross LabCell Corporation — Series A, Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Acuta Capital Partners (https://capitalatlas.ai/funds/acuta-capital-partners) — Series B
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series B
- Janus Henderson Investors — Series B
- Wellington Management Company — Series B
- Surveyor Capital — Series B
- Venrock Healthcare Capital Partners (https://capitalatlas.ai/funds/venrock-healthcare-capital-partners) — Series B
- Logos Capital (https://capitalatlas.ai/funds/logos-capital) — Series B